Evgen Pharma gets further protection for 'SFX-01' in Europe

Clinical stage drug development company Evgen Pharma announced the grant of further intellectual property rights in Europe pertaining to its novel composition ‘SFX-01’ on Wednesday.

The AIM-traded firm said the newly-granted patent led with a product claim covering "a composition comprising a complex of sulforaphane and alpha-cyclodextrin".

It said composition-of-matter patents had already been granted in the United States and other territories, and added that patents in Europe, the US and other territories relating to the method of production had also been granted.

Exclusive worldwide rights to the patent were held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs - the US laboratory that invented SFX-01.

“We are delighted by the grant of this important patent in Europe,” said Evgen Pharma chief executive officer Steve Franklin.

“This patent has broad claims relating to the composition of the novel drug substance, SFX-01, and as such represents a material development for the company.”

Franklin said it further expanded the “strength and depth” of the firm’s intellectual property position across its key territories, with regard to the composition of the product and the method of manufacture.

“The overall intellectual property position around SFX-01 and novel analogues has matured into an impressive patent estate, asserting our exclusive position around this new class of pharmaceutical.”